SB 1836, the SMART Prices Act, would amend the Medicare drug price negotiation provisions in title XVIII of the Social Security Act to make the Inflation Reduction Act’s drug pricing reforms more aggressive. The bill would increase the number of negotiation-eligible drugs selected in 2028 and later years from 15 to 50, substantially expanding the scope of the Medicare Drug Price Negotiation Program.
The bill also shortens the time before certain drugs can become eligible for negotiation by revising the definition of a qualifying single-source drug. Under current law, drugs generally must be on the market for 7 or 11 years, depending on the category; SB 1836 would reduce both thresholds to 3 years. In addition, it changes the ceiling for the maximum fair price by adjusting the percentage limits used in the pricing formula, which would generally allow for lower negotiated prices for Medicare.
If enacted, the bill would directly amend the Medicare statute and alter how the Centers for Medicare & Medicaid Services identifies drugs for negotiation and calculates negotiated prices. The practical effect would be to accelerate and broaden federal drug price negotiations, potentially increasing savings for Medicare and reducing out-of-pocket and taxpayer costs associated with high-priced prescription drugs.
The overall sentiment reflected by the bill’s sponsorship is strongly supportive of more aggressive drug pricing reform, with a large group of Democratic senators backing the measure. No committee debate or recorded votes are provided, so there is no documented opposition in the supplied materials. Based on the bill’s design, likely points of contention would be the expanded federal role in drug pricing, the faster timeline for negotiation eligibility, and the potential impact on pharmaceutical revenues and incentives for drug development.
Impact
SB 1836 would amend sections 1192 and 1194 of the Social Security Act to expand and accelerate Medicare drug price negotiations and revise the maximum fair price framework. It would increase the number of drugs selected for negotiation beginning in 2028 and later, shorten the age threshold for qualifying single-source drugs, and adjust the pricing ceiling formula. These changes would affect the Medicare program, the Centers for Medicare & Medicaid Services, drug manufacturers whose products become negotiation-eligible, and Medicare beneficiaries and taxpayers through potentially lower drug costs.
Sentiment
The bill appears to have a strongly pro-reform, cost-reduction orientation, reflected in its title and the large list of Democratic cosponsors. The available record shows introduction and referral to the Senate Finance Committee, but no committee transcript or vote data, so there is no formal recorded opposition or support beyond sponsorship. The general sentiment from the bill text is that supporters want to strengthen and speed up Medicare drug price negotiation to deliver lower prices more quickly.
Contention
The main likely points of contention are the bill’s expansion of federal authority over prescription drug pricing, the much larger number of drugs subject to negotiation, and the shortened timeline for eligibility. Pharmaceutical manufacturers and opponents of price controls would likely argue that the bill could reduce revenues and weaken incentives for innovation, while supporters would argue it would produce faster savings for Medicare beneficiaries and taxpayers. Because no hearing transcript or vote history is provided, these disputes are inferred from the policy changes rather than documented debate in the supplied materials.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.